Clinical Trials Browser

OTHER × Ovarian Neoplasms × Angiogenesis Inhibitors × Clear all

NCT06063070 2023-10-02

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Phase 2 Not yet recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms